ME03640B - Polipeptidi koji se vezuju za humani komplement c5 - Google Patents

Polipeptidi koji se vezuju za humani komplement c5

Info

Publication number
ME03640B
ME03640B MEP-2019-84A MEP201984A ME03640B ME 03640 B ME03640 B ME 03640B ME P201984 A MEP201984 A ME P201984A ME 03640 B ME03640 B ME 03640B
Authority
ME
Montenegro
Prior art keywords
human complement
polypeptides binding
polypeptides
binding
complement
Prior art date
Application number
MEP-2019-84A
Other languages
German (de)
English (en)
French (fr)
Inventor
Charlotta Berghard
Magnus Berglund
Patrik Strömberg
Malin Lindborg
Elin Gunneriusson
Joachim Feldwisch
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of ME03640B publication Critical patent/ME03640B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
MEP-2019-84A 2012-02-20 2013-02-19 Polipeptidi koji se vezuju za humani komplement c5 ME03640B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1250145 2012-02-20
EP13752233.0A EP2817329B1 (en) 2012-02-20 2013-02-19 Polypeptides binding to human complement c5
PCT/SE2013/050139 WO2013126006A1 (en) 2012-02-20 2013-02-19 Polypeptides binding to human complement c5

Publications (1)

Publication Number Publication Date
ME03640B true ME03640B (me) 2020-07-20

Family

ID=49006055

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-84A ME03640B (me) 2012-02-20 2013-02-19 Polipeptidi koji se vezuju za humani komplement c5

Country Status (31)

Country Link
US (4) US9808502B2 (me)
EP (2) EP3511339A1 (me)
JP (2) JP6276202B2 (me)
KR (2) KR102336895B1 (me)
CN (1) CN104114574B (me)
AU (3) AU2013222836B2 (me)
BR (1) BR112014020427B1 (me)
CA (1) CA2863862C (me)
CY (1) CY1121455T1 (me)
DK (1) DK2817329T3 (me)
ES (1) ES2715638T3 (me)
HK (1) HK1204790A1 (me)
HR (1) HRP20190522T1 (me)
HU (1) HUE041996T2 (me)
IL (2) IL234114B (me)
LT (1) LT2817329T (me)
ME (1) ME03640B (me)
MX (1) MX359201B (me)
MY (1) MY167232A (me)
NZ (1) NZ628625A (me)
PH (1) PH12014501604A1 (me)
PL (1) PL2817329T3 (me)
PT (1) PT2817329T (me)
RS (1) RS58503B1 (me)
RU (1) RU2654668C2 (me)
SG (1) SG11201404942UA (me)
SI (1) SI2817329T1 (me)
TR (1) TR201903840T4 (me)
UA (1) UA117096C2 (me)
WO (1) WO2013126006A1 (me)
ZA (1) ZA201406773B (me)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201903840T4 (tr) 2012-02-20 2019-04-22 Swedish Orphan Biovitrum Ab Publ İnsan tamamlayıcı C5'e bağlanan polipeptitler.
DK2912051T3 (en) 2012-10-25 2018-06-14 Affibody Ab PROCEDURE FOR SEPARATION OF PROTEINS CONTAINING AN ALBUMIN BINDING DOMAIN
ES2639099T3 (es) 2012-10-25 2017-10-25 Affibody Ab Polipéptido de unión a albúmina
PL3038633T3 (pl) * 2013-08-28 2021-07-19 Ipc Research, Llc Stabilne polipeptydy wiążące się z ludzkim dopełniaczem c5
KR20160068744A (ko) 2013-08-28 2016-06-15 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
RS59353B1 (sr) 2014-06-12 2019-10-31 Ra Pharmaceuticals Inc Modulacija aktivnosti komplementa
US10633423B2 (en) 2014-06-13 2020-04-28 Affibody Ab IL-6-binding polypeptide complex
CN106488930B (zh) * 2014-06-13 2021-11-02 阿菲博迪公司 新型多肽
DE102014225439A1 (de) * 2014-12-10 2016-06-16 Zf Friedrichshafen Ag Stufenplanet
WO2016113246A1 (en) * 2015-01-12 2016-07-21 Affibody Ab Il-17a-binding polypeptides
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
AU2016370210A1 (en) 2015-12-16 2018-06-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
AU2018301412A1 (en) * 2017-07-11 2020-01-30 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
WO2020198778A1 (en) 2019-04-03 2020-10-08 Clean Earth Technology Pty Ltd Materials and processes for recovering precious metals
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CA3172994A1 (en) * 2020-10-05 2022-04-14 Paul P. Tamburini Methods of treating dermatomyositis

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
EP0750458B1 (en) 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO1996009043A1 (en) 1994-09-23 1996-03-28 Alexion Pharmaceuticals, Inc. Methods for the treatment of inflammatory joint disease
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6534058B2 (en) 2000-10-10 2003-03-18 Tanox, Inc. Anti-C5 monoclonal antibodies
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
MX342385B (es) 2001-08-17 2016-09-27 Genentech Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b.
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2004050111A2 (en) 2002-12-02 2004-06-17 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2004106369A2 (en) 2003-06-02 2004-12-09 Evolutec Limited Complement inhibitors from ticks
US7348401B2 (en) 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7838244B2 (en) 2004-03-24 2010-11-23 Auckland Uniservices Limited SET1 proteins and uses thereof
EP1732613A2 (en) 2004-04-06 2006-12-20 Affibody AB Use of serum albumin binding peptides conjugates for the preparation of a medicament
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
EP3299027A1 (en) * 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
MX2008011323A (es) 2006-03-08 2008-11-18 Archemix Corp Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares.
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
US20100119530A1 (en) 2006-07-06 2010-05-13 Wenchao Song Regulation of TLR Signaling by Complement
EP3199549A1 (en) 2006-09-05 2017-08-02 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
AR062709A1 (es) * 2006-09-08 2008-11-26 Genentech Inc Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2008113834A2 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
CN101932337A (zh) 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
CN101765608B (zh) 2007-07-31 2015-03-11 阿菲博迪公司 新白蛋白结合组合物、方法及应用
WO2009030240A2 (en) 2007-09-05 2009-03-12 Immunobond Aps Method of determining functional deficiencies in the complement system
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
EP2837388A1 (en) * 2008-08-05 2015-02-18 Novartis AG Compositions and methods for antibodies targeting complement protein C5
SI2894165T1 (sl) 2008-11-10 2023-04-28 Alexion Pharmaceuticals, Inc. Postopki in sestavki za zdravljenje motenj povezanih s komplementom
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
RU2015145543A (ru) 2010-03-01 2019-01-11 Алексион Фармасьютикалз Инк. Способы и композиции для лечения болезни дего
US20110243942A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Relaxin-fusion proteins with extended in vivo half-lives
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
ES2676403T3 (es) 2010-07-09 2018-07-19 Affibody Ab Polipéptidos
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
TR201903840T4 (tr) 2012-02-20 2019-04-22 Swedish Orphan Biovitrum Ab Publ İnsan tamamlayıcı C5'e bağlanan polipeptitler.
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
EP2970406B1 (en) 2013-03-15 2017-12-13 Affibody AB New polypeptides
KR20160068744A (ko) 2013-08-28 2016-06-15 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
PL3038633T3 (pl) 2013-08-28 2021-07-19 Ipc Research, Llc Stabilne polipeptydy wiążące się z ludzkim dopełniaczem c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Also Published As

Publication number Publication date
US20190167760A1 (en) 2019-06-06
KR20140129163A (ko) 2014-11-06
HRP20190522T1 (hr) 2019-05-03
PL2817329T3 (pl) 2019-07-31
JP2015508652A (ja) 2015-03-23
MX2014009879A (es) 2014-11-10
SG11201404942UA (en) 2014-09-26
CN104114574A (zh) 2014-10-22
EP2817329A4 (en) 2015-09-02
MY167232A (en) 2018-08-14
AU2013222836A1 (en) 2014-09-18
EP2817329A1 (en) 2014-12-31
JP2018052942A (ja) 2018-04-05
JP6276202B2 (ja) 2018-02-07
HUE041996T2 (hu) 2019-07-29
EP3511339A1 (en) 2019-07-17
IL234114B (en) 2019-07-31
PT2817329T (pt) 2019-04-01
US11123401B2 (en) 2021-09-21
CA2863862C (en) 2021-03-16
AU2019250239B2 (en) 2021-04-08
RS58503B1 (sr) 2019-04-30
AU2019250239A1 (en) 2019-11-07
US20150011474A1 (en) 2015-01-08
DK2817329T3 (en) 2019-04-01
JP6719438B2 (ja) 2020-07-08
WO2013126006A1 (en) 2013-08-29
UA117096C2 (uk) 2018-06-25
RU2014137303A (ru) 2016-04-10
CN104114574B (zh) 2018-08-24
NZ628625A (en) 2016-03-31
TR201903840T4 (tr) 2019-04-22
PH12014501604B1 (en) 2014-10-08
US20210401930A1 (en) 2021-12-30
BR112014020427B1 (pt) 2023-04-04
PH12014501604A1 (en) 2014-10-08
IL267724B (en) 2022-05-01
CA2863862A1 (en) 2013-08-29
SI2817329T1 (sl) 2019-04-30
US9808502B2 (en) 2017-11-07
US20180085428A1 (en) 2018-03-29
CY1121455T1 (el) 2020-05-29
KR102149028B1 (ko) 2020-08-27
AU2013222836B2 (en) 2017-07-20
EP2817329B1 (en) 2019-01-02
KR20200105953A (ko) 2020-09-09
BR112014020427A8 (pt) 2018-01-23
MX359201B (es) 2018-09-19
IL267724A (en) 2019-08-29
ZA201406773B (en) 2016-08-31
RU2654668C2 (ru) 2018-05-21
HK1204790A1 (en) 2015-12-04
AU2017245376B2 (en) 2019-07-25
AU2017245376A1 (en) 2017-11-02
KR102336895B1 (ko) 2021-12-08
US10206975B2 (en) 2019-02-19
ES2715638T3 (es) 2019-06-05
LT2817329T (lt) 2019-04-10

Similar Documents

Publication Publication Date Title
IL267724B (en) Human c5 complement-binding polypeptides
IL291571A (en) cx3cr1 binding polypeptides
IL225439A0 (en) Polypeptides that bind to component 5c of the human complement system
IL233793B (en) mica binders
PL2900827T3 (pl) 3-epimeraza
GB201220474D0 (en) Polypeptides
HK1225656A1 (zh) 結合人類補體c5的穩定多肽
GB2506114B (en) Boot
EP2871213A4 (en) BELLY COMPOSITION
GB201420971D0 (en) Therapeutic composition
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
GB201203944D0 (en) Binding polypeptides
GB201218322D0 (en) Herbal composition
GB201213124D0 (en) Herbal composition
GB201214293D0 (en) Binding surfaces
AU2012195V (en) DC3000 Dianella caerulea